1. Home
  2. SRL vs ACET Comparison

SRL vs ACET Comparison

Compare SRL & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scully Royalty Ltd.

SRL

Scully Royalty Ltd.

N/A

Current Price

$8.61

Market Cap

83.0M

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$7.00

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRL
ACET
Founded
2017
1947
Country
China
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.0M
69.6M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
SRL
ACET
Price
$8.61
$7.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$65.33
AVG Volume (30 Days)
27.0K
134.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
11.71%
N/A
EPS Growth
N/A
59.82
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$0.45
52 Week High
$10.39
$9.05

Technical Indicators

Market Signals
Indicator
SRL
ACET
Relative Strength Index (RSI) 46.11 49.02
Support Level $8.66 $6.54
Resistance Level $9.60 $8.46
Average True Range (ATR) 0.29 0.47
MACD -0.08 -0.04
Stochastic Oscillator 30.00 33.10

Price Performance

Historical Comparison
SRL
ACET

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: